This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current
prognostic scoring systems aim to select patients for transplantation. Here, we aimed to …

The 2013 discovery of calreticulin (CALR) mutations in myeloproliferative neoplasms was
attended by their association with longer survival in primary myelofibrosis (PMF) …

Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) are a
heterogeneous group of clonal hematopoietic stem cell disorders characterized by an …

The role of spleen size and splenectomy for the prediction of post‐allogeneic hematopoietic
stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT …

Recurrent mutations in calreticulin are present in∼ 20% of patients with myeloproliferative
neoplasms (MPNs). Since its discovery in 2013, we now have a more precise understanding …

Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …

The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms
characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in …